Novartis (NVS) Receives FDA Approval for Afinitor Disperz Labeling Amendment
Tweet Send to a Friend
Novartis (NYSE: NVS) received FDA approval of a labeling revision for Afinitor Disperz (everolimus).In a letter to Novartis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
